Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604786 · ClinicalTrials.gov registry record · NA
The Effect of Omalizumab on Responses to Cat Allergen Challenge
A NA study of Allergic Rhinitis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00604786 is a NA study of Allergic Rhinitis that has completed, run by Johns Hopkins University. The registered enrollment target is 18 participants, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00604786, a NA study of Allergic Rhinitis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies. The investigators predict that cells in the blood will be effected before cells in the nose or skin.
Conditions Studied
Interventions
- DRUG placebo
- DRUG omalizumab
Study Locations (1)
Maryland
- Johns Hopkins Asthma and Allergy Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604786
The ClinicalTrials.gov registry entry for NCT00604786 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (83% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00604786 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00604786 about?
NCT00604786 is a clinical study titled "The Effect of Omalizumab on Responses to Cat Allergen Challenge". This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies. The investigators predict that cells in the blood will be effected befo...
What is the current status of trial NCT00604786?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2007-07. Estimated completion is 2009-01.
What conditions does trial NCT00604786 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT00604786?
The interventions under investigation include: placebo (DRUG), omalizumab (DRUG).
Who is sponsoring clinical trial NCT00604786?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00604786 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies
COMPLETED · NA
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.